{"id":"cetrorelix-78-78","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetrorelix competitively blocks GnRH receptors in the pituitary gland, rapidly suppressing the release of LH and FSH without an initial flare effect. This leads to decreased estrogen and progesterone production, making it useful for hormone-dependent conditions. The 78+78 designation likely refers to a dual-dose formulation or dosing regimen in development.","oneSentence":"Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:23.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (in combination with endocrine therapy)"},{"name":"Ovarian cancer (hormone-sensitive)"}]},"trialDetails":[{"nctId":"NCT00449150","phase":"PHASE3","title":"Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2007-03","conditions":"Benign Prostatic Hypertrophy","enrollment":667},{"nctId":"NCT00670306","phase":"PHASE3","title":"Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2008-03","conditions":"Benign Prostatic Hypertrophy","enrollment":528},{"nctId":"NCT00663858","phase":"PHASE3","title":"Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2008-03","conditions":"Benign Prostatic Hypertrophy","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cetrorelix 78+78","genericName":"Cetrorelix 78+78","companyName":"AEterna Zentaris","companyId":"aeterna-zentaris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production. Used for Hormone receptor-positive breast cancer (in combination with endocrine therapy), Ovarian cancer (hormone-sensitive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}